Biosceptre International Limited
- Home
- Companies
- Biosceptre International Limited
- Products
- Targeted Antibody Therapy
Targeted Antibody Therapy
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody structure, the same panel of antibody sequences can be used to generate a variety of therapeutic antibody formats including, but not limited to, monoclonal, bispecifics, antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs) in addition to our CAR-T program.
Most popular related searches
drug conjugate
T-cell
monoclonal antibody
therapeutic antibody
preclinical data
oncology drug
immune cell
immune system
drug development
cancer cell
Targeted antibody therapy is a form of immunotherapy that uses antibody-based drugs to bind specifically to certain proteins on targeted cells, with the aim of modulating the patient’s immune system to attack and kill the cancer cells without harming normal cells.
Immunoglobulin G (IgG) monoclonal antibodies (mAbs) are the predominant molecular format used in currently approved antibody drugs, with over 30 mAbs approved by the USFDA for various oncology indications.
Other antibody formats becoming increasingly common in oncology drug development include antibody drug conjugates, which are antibodies armed with toxins, and bispecific antibodies that recruit T cells or other immune cells to kill tumour cells.
Biosceptre is currently developing human-derived antibody therapeutics that target nfP2X7 for use in both solid and haematological tumours.